How to Approach and Manage Orthostatic Hypotension

Abstract

Orthostatic hypotension (OH) is a frequently undiagnosed condition, particularly affecting older adults and individuals with autonomic dysfunction. This comprehensive review offers a unique synthesis of current evidence on the aetiology, prevalence, diagnosis, and management of OH, integrating perspectives from neurology, cardiology, and geriatric medicine. It critically appraises the current limitations within clinical guidelines, highlighting the lack of standardised diagnostic protocols and the inadequate recognition of delayed OH and postural hypertension. Particular focus is given to the older population, proposing individualised diagnostic and therapeutic strategies to address their specific clinical vulnerabilities. By adopting a multidisciplinary, patient-centred framework, the review addresses the complexity of diagnosing and managing OH, emphasising both underutilised non-pharmacological interventions and the careful use of pharmacological therapies. It also calls for the urgent revision of national guidelines, including those by the National Institute for Health and Care Excellence, to align with contemporary evidence and improve clinical decision-making. Future research directions are proposed, particularly regarding symptomatic versus asymptomatic OH, the development of refined diagnostic tools, and the long-term impact of symptom control.

Graphical abstract

Keywords

orthostatic hypotension / postural hypotension / syncope

1. Introduction

Orthostatic hypotension (OH) is a prevalent yet frequently underdiagnosed condition, particularly affecting older adults and individuals with autonomic dysfunction [1]. It is clinically defined as a sustained decrease in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within three minutes of standing or following a head-up tilt of at least 60 degrees [1]. OH often presents with symptoms such as dizziness, visual disturbances, syncope, and generalised weakness, and it is associated with an increased risk of falls, cognitive decline, depression, cardiovascular disease, and mortality [2, 3]. According to the National Institute for Health and Care Excellence [4], inpatients aged 65 years and over, as well as those between 50 and 64 years with predisposing conditions, are deemed at high risk for falls and should have their blood pressure measured both in lying and standing positions upon admission. The management of OH in older adults necessitates an individualised approach that prioritises non-pharmacological strategies, careful medication review, and balancing fall risk against blood pressure targets, recognising the vulnerability of this population to both hypotension and adverse drug effects. OH significantly impairs patients’ quality of life, contributing to recurrent falls, loss of independence, reduced functional capacity, and psychological consequences such as fear of falling and depression [5]. From a health economic perspective, OH is associated with increased healthcare resource utilisation, including higher rates of hospital admissions, emergency department attendances, and prolonged inpatient stays, particularly among older adults [6]. The cumulative burden of OH on healthcare systems underscores the urgent need for improved recognition, standardised diagnostic pathways, and evidence-based management strategies aimed at reducing morbidity, mortality, and associated costs.

Despite its significant clinical consequences, the diagnosis and management of OH are constrained by inconsistent screening practices, outdated national guidelines, and variability in therapeutic approaches. Existing reviews often address singular aspects of OH; however, this review uniquely integrates evidence from neurology, cardiology, and geriatric medicine, offering a comprehensive multidisciplinary perspective. It critically examines the limitations within current practice, emphasises the need to recognise delayed OH and postural hypertension, and advocates for a patient-centred, evidence-based management strategy. Given the increasing burden of OH in ageing populations and its association with significant morbidity and mortality, a standardised and updated approach to its diagnosis and treatment is urgently required. The following section discusses the epidemiology of OH.

2. What Is the Epidemiology of OH?

The prevalence of OH increases with age, though it varies depending on underlying medical conditions and population characteristics. Systematic reviews estimate that OH affects 19% to 22% of community-dwelling adults, but this figure fluctuates based on study cohorts [7, 8]. Large-scale population studies in the USA indicate a prevalence of less than 5% in individuals under 54 years of age, rising to approximately 14% among those aged 65–69 years and exceeding 20% in individuals aged 80 years and older [9].

A systematic review and meta-analysis of 26 studies involving over 25,000 participants further examined the prevalence of OH in older adults [8]. This study included individuals aged 60 years and older from both community and long-term care settings. OH was found in 22.2% of community-dwelling adults and 23.9% of those in long-term care facilities. However, significant heterogeneity (I² > 90%) was observed, primarily due to methodological differences such as variations in supine rest duration, blood pressure measurement protocols, and diagnostic criteria. Despite these differences, the findings confirm that OH is a common condition in ageing populations, associated with an increased risk of falls, cognitive decline, and mortality. Consequently, the study underscores the need for standardised diagnostic protocols to improve accuracy and optimise clinical management.

OH is particularly prevalent among individuals with neurodegenerative disorders. Approximately one-third of patients with Parkinson’s disease are affected by OH, largely due to autonomic dysfunction associated with neurodegeneration [10].

Among institutionalised older adults, the prevalence is notably higher, affecting 31% to 37% of nursing home residents and reaching 68% in geriatric inpatients [7, 11, 12]. Cremer et al. [13] further highlighted that OH is common among geriatric inpatients, with its prevalence influenced by factors such as clinical settings, mobilisation efforts, and the frequency of blood pressure assessments. The increased prevalence in care settings is likely due to the cumulative burden of risk factors, including neurodegenerative disorders, polypharmacy (e.g., antihypertensives, antidepressants), and reduced physical activity leading to deconditioning. Given its strong association with frailty, OH represents a significant clinical concern in older populations, necessitating early detection and appropriate management to mitigate its impact on morbidity and quality of life.

3. What Are the Aetiological Factors Contributing to OH?

3.1 Neurogenic Causes

3.1.1 Ageing and Reduced Autonomic Buffering

Ageing is inherently linked to a decline in autonomic buffering capacity, which compromises the physiological adaptation to orthostatic stress [14]. This predisposes older individuals to OH, a condition exacerbated by various pharmacological agents, including alpha-blockers prescribed for benign prostatic hypertrophy, central sympatholytic medications such as tizanidine and methyldopa, tricyclic antidepressants, phosphodiesterase-5 inhibitors for erectile dysfunction, and a range of antihypertensive agents, including beta-blockers [15]. Additionally, vascular stiffening due to atherosclerosis, physical deconditioning, and hypertension contribute to impaired compensatory mechanisms, increasing susceptibility to OH [7].

3.1.2 Autonomic Dysfunction

Neurogenic OH arises due to autonomic dysfunction, frequently occurring in conditions such as diabetes mellitus and amyloidosis, where peripheral neuropathy leads to autonomic impairment [16]. Furthermore, neurodegenerative disorders, including Parkinson’s disease and dementia with Lewy bodies, are commonly associated with autonomic dysfunction, resulting in OH of varying severity [17]. Less prevalent but clinically significant disorders affecting the autonomic nervous system include pure autonomic failure, a synucleinopathy primarily affecting peripheral autonomic nerves without concurrent movement disorder, and multiple system atrophy (MSA), which presents with either parkinsonian (MSA-P) or cerebellar (MSA-C) phenotypes, both exhibiting severe autonomic failure, including OH.

3.1.3 Autoimmune and Paraneoplastic

Autoimmune autonomic ganglionopathy represents another potential cause of autonomic failure and OH, often characterised by the presence of antibodies targeting the nicotinic acetylcholine receptor at autonomic ganglia. Additionally, paraneoplastic syndromes, most notably those associated with small-cell lung cancer, monoclonal gammopathies, or light-chain diseases, can result in autonomic dysfunction, manifesting as OH. Given the diverse aetiological spectrum, a thorough assessment is essential to distinguish neurogenic from non-neurogenic causes, ensuring accurate diagnosis and targeted management of OH.

3.2 Non-Neurogenic Causes

Non-neurogenic causes are more prevalent and involve multiple physiological disruptions. Volume depletion, resulting from dehydration, haemorrhage, or hyperglycaemia, significantly contributes to OH. Cardiovascular diseases, including aortic stenosis, heart failure, and arrhythmias, can impair circulatory responses to postural changes. In addition, adrenal insufficiency, prolonged immobilisation, and physical deconditioning further increase the risk. In addition, peripheral neuropathies, often secondary to conditions such as diabetes mellitus, vitamin B12 deficiency, renal failure, amyloidosis, and autoimmune or paraneoplastic syndromes, can lead to autonomic dysfunction, further increasing susceptibility to OH. A systematic review and meta-analysis encompassing 21 studies with 13,722 patients found that approximately 25% of individuals with diabetes experience OH [18]. High glycated haemoglobin (HbA1c) levels, hypertension, and diabetic neuropathy significantly increase the risk [19].

3.2.1 Medication-Induced OH

Pharmacological agents play a major role in OH by reducing blood volume or interfering with autonomic regulation [20]. These include antihypertensives (Table 1, Ref. [21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31]), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics, and beta-blockers. Rather than a single drug class being primarily responsible, evidence suggests that the cumulative number of antihypertensive medications prescribed is a stronger predictor of OH [3]. Individual susceptibility varies based on age, comorbidities, and polypharmacy. Moreover, a recent meta-analysis of randomised controlled trials presents additional evidence that medications inducing sympathetic inhibition are significantly linked to an increased likelihood of OH. In contrast, drugs that primarily exert vasodilatory effects do not demonstrate a similar association [21].

3.2.2 Hypertension and OH

Hypertension is paradoxically associated with OH due to mechanisms such as reduced diastolic filling, arterial stiffness, and an exaggerated threshold effect in individuals with high supine or seated blood pressure [7]. This impaired baroreceptor sensitivity hinders the compensatory responses required to maintain blood pressure upon standing, increasing the likelihood of OH episodes.

3.2.3 Alcohol Consumption and OH

Alcohol consumption contributes to OH through both acute and chronic mechanisms [32]. Short-term effects include vasodilation and impaired vasoconstriction, leading to transient OH. Chronic alcohol use, due to its neurotoxic effects, results in autonomic dysfunction, making it a potential neurogenic cause of OH.

3.3 Idiopathic OH

In some cases, OH occurs without a clearly identifiable cause, termed idiopathic OH [33]. This remains a diagnostic challenge, necessitating comprehensive evaluation to rule out secondary causes and optimise management strategies.

4. How Should History-Taking and Clinical Examination Be Conducted in Patients With Suspected OH?

A thorough history and clinical examination are essential in assessing patients with suspected OH to determine underlying causes, which are often multifactorial. The history should focus on the nature, onset, and triggers of symptoms, while the examination aims to identify associated autonomic dysfunction, neurological abnormalities, and cardiovascular pathology.

4.1 History-Taking

A holistic history is crucial for identifying OH, as patients commonly report light-headedness, dizziness, visual disturbances (tunnel vision or blackouts), and generalised weakness [4]. Symptoms should be assessed in relation to changes in posture, worsening on standing, and improvement upon sitting or lying down [34]. Some patients, particularly those with cognitive impairment, may struggle to articulate their symptoms and instead present with unexplained falls or transient episodes of unresponsiveness. Aggravating factors such as prolonged standing, early morning hours, postprandial states, hot environments, or recent physical exertion should be explored, as these can exacerbate OH due to reduced circulatory compensation [3].

A history of neuropathy should be sought, as small-fibre peripheral neuropathies affecting the lower extremities may indicate underlying autonomic dysfunction [35]. Patients may report symptoms such as burning pain, tingling, or numbness, commonly associated with diabetes mellitus but also seen in conditions such as amyloidosis, autoimmune disorders, or chronic kidney disease. A subacute or acute onset of severe, disabling OH may suggest an autoimmune autonomic ganglionopathy, particularly if preceded by a viral-like illness [3]. In some cases, OH may be a manifestation of a paraneoplastic syndrome, warranting a thorough review of symptoms such as unexplained weight loss or malignancy-associated conditions [36].

Medication history is a key component of the assessment, as OH can be drug-induced [20]. Agents such as alpha-blockers, beta-blockers, nitrates, diuretics, antidepressants, and antipsychotics can impair autonomic responses or reduce intravascular volume, increasing susceptibility to OH. Polypharmacy and recent medication adjustments should also be reviewed, particularly in elderly patients.

4.2 Clinical Examination

The physical examination should focus on confirming the diagnosis of OH and identifying any underlying neurological or cardiovascular abnormalities. Blood pressure and heart rate should be measured in both supine and standing positions, with a drop in systolic blood pressure of \ge20 mmHg or diastolic blood pressure of \ge10 mmHg upon standing being diagnostic of OH. If symptoms are intermittent, repeated measurements may be necessary, including assessment after meals or early in the morning when symptoms are more pronounced.

Neurological examination is crucial, as features such as bradykinesia, rigidity, resting tremor, and hypomimia may indicate Parkinson’s disease or multiple system atrophy, both of which are associated with autonomic dysfunction. Cerebellar signs, including ataxia of gait and dysarthria, may suggest multiple system atrophy with predominant cerebellar involvement. In addition, autonomic features such as reduced or excessive sweating, heat intolerance, dry skin, or focal hyperhidrosis may indicate a primary autonomic failure.

Cardiovascular assessment should include auscultation for murmurs suggestive of structural heart disease, such as aortic stenosis, which can contribute to OH. The presence of resting tachycardia or impaired heart rate variability may suggest autonomic neuropathy, particularly in patients with diabetes. Symptoms of gastrointestinal dysmotility, including early satiety, constipation, or bloating, should be assessed, as these are frequently seen in patients with autonomic dysfunction and may precede the development of OH in neurodegenerative disorders. Bladder function should also be evaluated, as urinary frequency, urgency, and nocturia are common in patients with autonomic failure. These symptoms can be particularly pronounced in multiple system atrophy and Parkinson’s disease, where nocturnal hypertension contributes to increased overnight urine production, worsening OH symptoms in the morning. Erectile dysfunction and absent ejaculation in male patients may further indicate autonomic involvement.

A comprehensive approach combining history-taking and clinical examination is vital in identifying the underlying cause of OH and guiding appropriate management. Given the often-multifactorial nature of OH, an interdisciplinary approach involving neurology, cardiology, and geriatric medicine may be necessary for optimal patient care.

5. What Investigations Are Required to Diagnose OH?

A systematic approach to diagnosing OH requires a combination of clinical assessment, bedside measurements, and targeted laboratory and autonomic function tests. The aim is to confirm the presence of OH, distinguish between neurogenic and non-neurogenic causes, and identify any underlying conditions contributing to autonomic dysfunction.

5.1 Clinical Diagnosis of OH

The diagnosis of OH is confirmed through a structured blood pressure assessment in different postural positions (Fig. 1, Ref. [37]). According to the Royal College of Physicians [38], blood pressure should be measured after the patient has been lying supine for at least five minutes, followed by a second reading within the first minute of standing, and a third measurement after three minutes of standing. If blood pressure continues to drop, additional recordings may be necessary. Any symptoms experienced during postural change should be documented. A diagnosis of OH is confirmed if there is a systolic blood pressure reduction of 20 mmHg or more upon standing, a systolic pressure drops below 90 mmHg regardless of their symptoms or less than 20 mmHg, or a diastolic pressure drop of 10 mmHg with symptoms, though systolic changes are considered more clinically relevant.

5.2 Other Investigations for Exclusion of Diseases

It is also advisable to record heart rate responses, as a rise of 15 beats per minute suggests a neurogenic cause, whereas a greater increase may indicate non-neurogenic OH. However, beta-blocker use can reduce heart rate, limiting its diagnostic value. In patients with fluctuating symptoms or suspected nocturnal hypertension, 24-hour ambulatory blood pressure monitoring can be useful. This can help detect supine hypertension, which is present in up to 50% of patients with autonomic failure, as well as early morning and postprandial hypotension when accompanied by a symptom diary. Table 2 (Ref. [39, 40, 41, 42, 43, 44]) outlines the additional investigations of OH.

6. How Do Current Guidelines for Measuring Blood Pressure Detect OH, and What Are Their Limitations?

Current guidelines for detecting OH vary in definitions, measurement protocols, and limitations (Table 3, Ref. [37, 45, 46, 47, 48, 49, 50]). While most define OH as a fall in systolic blood pressure (SBP) \ge20 mmHg or diastolic blood pressure (DBP) \ge10 mmHg, discrepancies exist in initial positioning (supine vs. seated), timing of measurements, and symptom documentation. Some guidelines fail to account for delayed OH, while others lack standardised thresholds, potentially leading to underdiagnosis or inconsistent assessments.

7. Who Should Be Investigated for OH?

Current guidelines recommend targeted screening rather than routine population-wide testing. The NICE [4] suggests measuring postural blood pressure in symptomatic patients or those who have experienced a fall. Screening is also advised for patients with hypertension and type 2 diabetes or those over the age of 80 with hypertension.

The American Diabetes Association recommends periodic OH assessment in patients with diabetes, even if asymptomatic. In addition, expert consensus suggests screening individuals diagnosed with neurodegenerative conditions associated with autonomic dysfunction (e.g., Parkinson’s disease, multiple system atrophy) and those with peripheral neuropathies known to affect autonomic function, such as diabetic neuropathy.

Table 4 (Ref. [51, 52]) [3, 4, 26] outlines the differential diagnosis that healthcare professionals should consider when approaching a patient with OH.

8. What Are the Current Management Strategies for OH?

The management of OH primarily focuses on alleviating symptoms and preventing complications such as falls and syncope [4]. Treatment is generally reserved for symptomatic patients, as the clinical significance of asymptomatic OH remains uncertain. A multifaceted approach is required, encompassing identification and reversal of underlying causes, patient education, non-pharmacological strategies, and pharmacological interventions when necessary.

8.1 Addressing Reversible Causes

A key aspect of OH management involves identifying and addressing modifiable contributors. Medication review is essential, as many commonly prescribed drugs, such as antihypertensives, diuretics, tricyclic antidepressants, and alpha-blockers, can contribute to OH. If a drug-induced cause is suspected, adjustments should be made by either discontinuing, reducing the dose, switching to a modified-release preparation, or substituting with an alternative agent. Care should be taken to ensure that the underlying condition for which the medication was prescribed remains adequately managed.

Other reversible factors include dehydration, infection, anaemia, and electrolyte imbalances, all of which should be corrected where possible. Further investigations should be guided by the patient’s clinical presentation. Blood tests (e.g., full blood count, electrolytes, renal function, HbA1c, vitamin B12 levels) may be warranted to rule out systemic contributors such as diabetes, renal impairment, or vitamin deficiencies. If arrhythmias or structural heart disease are suspected, an electrocardiogram (ECG) and echocardiogram may be appropriate. Furthermore, a referral to falls clinic/syncope or memory clinic might be required as well.

8.2 Non-Pharmacological Management

Non-pharmacological interventions are essential in the management of OH, particularly in patients where pharmacological therapy is contraindicated or insufficient. Patient education is central to self-management. Individuals should be informed about the pathophysiology of OH, common exacerbating factors, and preventive strategies. They should avoid prolonged standing, sudden postural changes, large meals, alcohol consumption, dehydration, and exposure to excessive heat. Hot showers and straining should similarly be minimised, as these contribute to vasodilation and intravascular volume depletion, thereby worsening symptoms.

Physical counter-manoeuvres are frequently employed to reduce orthostatic symptoms. Techniques such as leg crossing, squatting, and tensing lower limb muscles before or during standing can augment venous return and limit blood pressure decline. In addition, compression garments—such as abdominal binders or thigh-high stockings—may assist in reducing venous pooling, although their practicality may be limited by discomfort or difficulties in application [53].

Optimisation of hydration status is recommended, including maintaining sufficient fluid intake and, where not contraindicated (e.g., in hypertension or heart failure), increasing dietary salt to expand plasma volume [26]. Postural changes should be performed gradually to allow compensatory autonomic responses to occur. Elevating the head of the bed by approximately 30 degrees can help to reduce nocturnal supine hypertension, which is commonly associated with autonomic dysfunction in OH [26].

Further strategies include leg elevation and active counter-manoeuvres to diminish peripheral venous pooling [26]. Postprandial hypotension, which contributes to symptom burden in many patients, can be addressed by reducing meal size, increasing meal frequency, and limiting carbohydrate-rich foods to prevent splanchnic vasodilation [26]. While compression stockings are often proposed to improve venous return, current evidence supporting their effectiveness is limited. Comparatively, abdominal compression has demonstrated greater efficacy in reducing splanchnic pooling; however, its routine use may be hindered by issues of comfort and patient adherence [53].

8.3 Pharmacological Management

When non-pharmacological interventions fail to adequately control the symptoms of OH, pharmacological treatments may be considered. Midodrine, an alpha-adrenergic agonist, is often the first-line therapy; it induces vasoconstriction, thereby increasing standing blood pressure. It is typically initiated at 2.5 mg three times daily during waking hours and may be titrated by increments of 2.5 mg every three to seven days, up to a maximum of 10 mg three times daily [54]. Common adverse effects include supine hypertension, piloerection, pruritus, and urinary retention; therefore, blood pressure should be monitored in both supine and standing positions, and patients should be advised to avoid lying flat shortly after dosing.

Fludrocortisone, a mineralocorticoid, enhances sodium retention and expands plasma volume, contributing to improved blood pressure stability. It is initiated at a dose of 100 micrograms once daily, with gradual escalation by 50–100 micrograms as needed, not exceeding 300 micrograms daily [55]. Monitoring should include blood pressure, serum electrolytes, and fluid status, as fludrocortisone may precipitate fluid overload, hypertension, hypokalaemia, and, in some cases, heart failure.

Other pharmacological options include droxidopa, a norepinephrine precursor that augments sympathetic tone, initiated at 100 mg three times daily, with titration by 100 mg every 24–48 hours to a maximum of 600 mg three times daily, while monitoring for supine hypertension, headache, and nausea [3]. Pyridostigmine, a cholinesterase inhibitor that enhances autonomic function, is often reserved for milder cases and may be commenced at 30–60 mg twice daily, with gastrointestinal side effects such as diarrhoea and abdominal cramps being the most common limitations to its use. In refractory cases, a combination of these agents may be required under specialist supervision to achieve optimal symptom control.

9. What Are the Complications Associated With OH?

OH has significant clinical implications, affecting both functional ability and long-term health outcomes. It can impair balance and mobility, thereby increasing the risk of falls and reducing the ability to perform activities of daily living. The impact of OH extends beyond transient symptoms of dizziness or syncope, as it is strongly linked to cardiovascular disease, cerebrovascular events, cognitive decline, and increased mortality.

Individuals with OH are at a markedly higher risk of falls, with studies indicating an approximately 1.73-fold increased likelihood compared to those without OH. This is particularly concerning in older adults, where falls can lead to fractures, hospitalisation, and loss of independence.

OH has been associated with a greater incidence of heart failure, with a hazard ratio of 1.34, highlighting the potential role of haemodynamic instability in worsening cardiac function in experimental laboratory research [56]. The risk of coronary heart disease is also elevated (hazard ratio 1.44), suggesting that recurrent episodes of cerebral and myocardial hypoperfusion may contribute to vascular damage and ischaemic events.

Cerebrovascular complications are another major concern, with OH linked to a 1.64-fold increased risk of stroke, possibly due to inadequate cerebral perfusion during hypotensive episodes. The association with atrial fibrillation (hazard ratio 1.51) further highlights the complex cardiovascular consequences of OH, as impaired autonomic regulation and blood pressure fluctuations may predispose individuals to arrhythmias [56]. These cardiovascular risks collectively contribute to a 50% increased risk of all-cause mortality, as demonstrated in a meta-analysis of large-scale prospective observational studies [57]. Emerging evidence from smaller studies suggests that OH may also have detrimental effects on cognitive function, increasing the risk of dementia and cognitive impairment [58, 59]. Chronic cerebral hypoperfusion is thought to play a role in neurodegenerative processes, potentially accelerating cognitive decline. Furthermore, a potential link between OH and depression has been suggested, though the exact mechanisms remain unclear.

The degree to which these risks vary between symptomatic and asymptomatic individuals remains uncertain, as does the influence of age on these outcomes. However, given the broad spectrum of adverse effects associated with OH, early identification and appropriate management are crucial to reducing morbidity and improving quality of life.

10. What Is Postural Hypertension, and How Does It Relate to OH?

Postural hypertension is a phenomenon where blood pressure rises rather than falls upon standing [60]. Unlike OH, which is well-documented and widely recognised, postural hypertension remains under-researched, and its clinical significance is not fully understood. While some definitions classify it as an increase in systolic blood pressure of 20 mmHg or more, variations in study criteria have led to inconsistent prevalence estimates [61]. The mechanisms underlying postural hypertension are not entirely clear, but it is thought to be associated with increased vascular resistance, altered autonomic control, and impaired baroreceptor function. It has been observed in individuals with conditions such as hypertension, diabetes, and neurodegenerative diseases, suggesting a possible link to autonomic dysfunction. In some cases, it may reflect excessive sympathetic activation, while in others, it could indicate vascular stiffness or dysregulated blood pressure responses to positional changes. Emerging evidence suggests that postural hypertension may be linked to an increased risk of cardiovascular events, including heart failure, stroke, and mortality [61]. However, there is ongoing debate about whether it represents a compensatory mechanism or a pathological condition requiring intervention.

It seems that current guidelines, such as NICE, are outdated; therefore, clinical guidelines should be revised to incorporate recent findings on non-pharmacological strategies, symptom prioritisation, and drug-induced hypotension. Future research should not only examine the comparative effectiveness of treatments for classical and delayed OH but also define optimal follow-up strategies for high-risk populations. Patients with underlying neurological conditions, such as Parkinson’s disease or multiple system atrophy, require structured follow-up, including regular assessment of fall history, lying and standing blood pressure measurements, evaluation for supine hypertension, and screening for cardiovascular events. It is advisable that follow-up occurs at intervals of three to six months initially, with more frequent review if new symptoms develop or treatment adjustments are made. Clear follow-up protocols would support earlier identification of clinical deterioration, guide treatment modifications, and ultimately improve long-term outcomes in this vulnerable group.

11. Conclusion

Effective management of OH requires a comprehensive, multidisciplinary approach that prioritises patient education, lifestyle modifications, and, where necessary, pharmacological interventions. Non-pharmacological strategies, such as maintaining adequate hydration, gradual postural changes, and physical counter-manoeuvres, play a central role, with pharmacological agents such as midodrine and fludrocortisone reserved for more severe or refractory cases. Early recognition and individualised treatment are critical to improving clinical outcomes and reducing complications, particularly in older adults who are at increased risk. The inclusion of postural hypertension in this review reflects the need to recognise the full spectrum of orthostatic blood pressure abnormalities, as postural hypertension may coexist with OH and influence diagnosis, risk stratification, and therapeutic decisions.

Key Points

\bullet Comprehensive management of OH involves addressing reversible causes, implementing non-pharmacological strategies, and considering pharmacological treatments when necessary.

\bullet Patient education is crucial; individuals should be informed about OH’s pathophysiology, common triggers, and preventive measures to empower effective self-management.

\bullet Non-pharmacological interventions such as physical counter-manoeuvres (e.g., leg crossing, squatting), compression garments, and gradual postural transitions can significantly reduce symptoms and improve quality of life.

\bullet Pharmacological treatments such as midodrine and fludrocortisone may be used when non-pharmacological measures are insufficient, but they require careful monitoring due to potential side effects.

Availability of Data and Materials

Not applicable.

References

[1] Kaski D, Furman JM. Dizziness in the elderly. In Bronstein AM (ed.) Oxford Textbook of Vertigo and Imbalance (pp. 433). Oxford University Press: Oxford. 2025.

[2] Fanty LF, Gibbons CH. Orthostatic Hypotension and Sudomotor Dysfunction in Diabetes. In Diabetic Neuropathy: Advances in Pathophysiology and Clinical Management (pp. 453–469). Springer International Publishing: Cham. 2023.

[3] Biaggioni I, Norcliffe-Kaufmann L, Kaufmann H. Orthostatic hypotension. BMJ Best Practice. 2025. Available at: https://bestpractice.bmj.com/topics/en-gb/972/aetiology (Accessed: 22 March 2025).

[4] National Institute for Health and Care Excellence (NICE). Falls: assessment and prevention in older people and in people 50 and over at higher risk (NICE guideline NG249). London: NICE. 2025. Available at: https://www.nice.org.uk/guidance/ng249/resources/falls-assessment-and-prevention-in-older-people-and-in-people-50-and-over-at-higher-risk-pdf-66143964997573 (Accessed: 8 July 2025).

[5] Arik F, Soysal P, Capar E, Kalan U, Smith L, Trott M, et al. The association between fear of falling and orthostatic hypotension in older adults. Aging Clinical and Experimental Research. 2021; 33: 3199–3204. https://doi.org/10.1007/s40520-020-01584-2.

[6] Duggan E, Romero-Ortuno R, Kenny RA. Admissions for orthostatic hypotension: an analysis of NHS England Hospital Episode Statistics data. BMJ Open. 2019; 9: e034087. https://doi.org/10.1136/bmjopen-2019-034087.

[7] McDonagh STJ, Mejzner N, Clark CE. Prevalence of postural hypotension in primary, community and institutional care: a systematic review and meta-analysis. BMC Family Practice. 2021; 22: 1. https://doi.org/10.1186/s12875-020-01313-8.

[8] Saedon NI, Pin Tan M, Frith J. The Prevalence of Orthostatic Hypotension: A Systematic Review and Meta-Analysis. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2020; 75: 117–122. https://doi.org/10.1093/gerona/gly188.

[9] Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. American Journal of Hypertension. 2011; 24: 135–144. https://doi.org/10.1038/ajh.2010.146.

[10] Palma JA, Kaufmann H. Orthostatic Hypotension in Parkinson Disease. Clinics in Geriatric Medicine. 2019; 36: 53–67. https://doi.org/10.1016/j.cger.2019.09.002.

[11] Hartog LC, Cizmar-Sweelssen M, Knipscheer A, Groenier KH, Kleefstra N, Bilo HJG, et al. The association between orthostatic hypotension, falling and successful rehabilitation in a nursing home population. Archives of Gerontology and Geriatrics. 2015; 61: 190–196. https://doi.org/10.1016/j.archger.2015.05.005.

[12] Hartog LC, Cimzar-Sweelssen M, Knipscheer A, Groenier KH, Kleefstra N, Bilo HJG, et al. Orthostatic hypotension does not predict recurrent falling in a nursing home population. Archives of Gerontology and Geriatrics. 2017; 68: 39–43. https://doi.org/10.1016/j.archger.2016.08.011.

[13] Cremer A, Rousseau AL, Boulestreau R, Kuntz S, Tzourio C, Gosse P. Screening for orthostatic hypotension using home blood pressure measurements. Journal of Hypertension. 2019; 37: 923–927. https://doi.org/10.1097/HJH.0000000000001986.

[14] Takla M, Saadeh K, Tse G, Huang CLH, Jeevaratnam K. Ageing and the Autonomic Nervous System. In Biochemistry and Cell Biology of Ageing: Part IV, Clinical Science (pp. 201–252). Springer International Publishing: Cham. 2023.

[15] Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th edn. McGraw Hill LLC: New York. 2020.

[16] Roth B, Schiro DB, Ohlsson B. Diseases which cause generalized peripheral neuropathy: a systematic review. Scandinavian Journal of Gastroenterology. 2021; 56: 1000–1010. https://doi.org/10.1080/00365521.2021.1942542.

[17] Loureiro D, Bilbao R, Bordet S, Grasso L, Otero-Losada M, Capani F, et al. A systematic review and meta-analysis on the association between orthostatic hypotension and mild cognitive impairment and dementia in Parkinson’s disease. Neurological Sciences. 2023; 44: 1211–1222. https://doi.org/10.1007/s10072-022-06537-3.

[18] Zhou Y, Ke SJ, Qiu XP, Liu LB. Prevalence, risk factors, and prognosis of orthostatic hypotension in diabetic patients: A systematic review and meta-analysis. Medicine. 2017; 96: e8004. https://doi.org/10.1097/MD.0000000000008004.

[19] Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RMA. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism & Related Disorders. 2011; 17: 724–729. https://doi.org/10.1016/j.parkreldis.2011.04.016.

[20] Kadioglu SB, Celik T. Orthostatic hypotension and drugs: drug-induced orthostatic hypotension. In Isik AT, Soysal P (eds.) Orthostatic Hypotension in Older Adults (pp. 45–59). Springer: Cham. 2021.

[21] Bhanu C, Nimmons D, Petersen I, Orlu M, Davis D, Hussain H, et al. Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials. PLoS Medicine. 2021; 18: e1003821. https://doi.org/10.1371/journal.pmed.1003821.

[22] Biaggioni I. Orthostatic Hypotension in the Hypertensive Patient. American Journal of Hypertension. 2018; 31: 1255–1259. https://doi.org/10.1093/ajh/hpy089.

[23] Rivasi G, Rafanelli M, Mossello E, Brignole M, Ungar A. Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. Drugs & Aging. 2020; 37: 725–738. https://doi.org/10.1007/s40266-020-00796-5.

[24] Godbole GP, Aggarwal B. Review of management strategies for orthostatic hypotension in older people. Journal of Pharmacy Practice and Research. 2018; 48: 484–492. https://doi.org/10.1002/jppr.1484.

[25] Juraschek SP, Cortez MM, Flack JM, Ghazi L, Kenny RA, Rahman M, et al. Orthostatic Hypotension in Adults With Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2024; 81: e16–e30. https://doi.org/10.1161/HYP.0000000000000236.

[26] Ringer M, Hashmi MF, Lappin SL. Orthostatic hypotension. StatPearls [Internet]. StatPearls Publishing: Treasure Island, FL. 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK448192/ (Accessed: 22 March 2025).

[27] Yulistiani Y, Utomo FN, Nugroho CW, Izzati YN. Analysis of fall risk increasing drugs on Morse Fall Scale in geriatric patients (a study at geriatric outpatient clinic Airlangga University Teaching Hospital). Pharmacia. 2023; 70: 263–274.

[28] Shimbo D, Barrett Bowling C, Levitan EB, Deng L, Sim JJ, Huang L, et al. Short-term risk of serious fall injuries in older adults initiating and intensifying treatment with antihypertensive medication. Circulation: Cardiovascular Quality and Outcomes. 2016; 9: 222–229.

[29] Raber I, Belanger MJ, Farahmand R, Aggarwal R, Chiu N, Al Rifai M, et al. Orthostatic Hypotension in Hypertensive Adults: Harry Goldblatt Award for Early Career Investigators 2021. Hypertension. 2022; 79: 2388–2396. https://doi.org/10.1161/HYPERTENSIONAHA.122.18557.

[30] McKeever RG, Patel P, Hamilton RJ. Calcium channel blockers. StatPearls [Internet]. StatPearls Publishing. 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482473/ (Accessed: 28 March 2025).

[31] Juraschek SP, Simpson LM, Davis BR, Beach JL, Ishak A, Mukamal KJ. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial. Hypertension. 2019; 74: 1033–1040. https://doi.org/10.1161/HYPERTENSIONAHA.119.13445.

[32] Forsah SF, Ugwendum D, Arrey Agbor DB, Ndema N, Ndemazie NB, Kankeu Tonpouwo G, et al. Syncope Secondary to Concomitant Ingestion of Tizanidine and Alcohol in a Patient With Alcohol Use Disorder. Cureus. 2024; 16: e57249. https://doi.org/10.7759/cureus.57249.

[33] Aminoff MJ. Dysautonomia, Postural Hypotension, and Syncope. In Aminoff MJ, Josephson SA (eds.) Aminoff’s Neurology and General Medicine (pp. 123). 6th edn. Academic Press: London. 2021.

[34] Kim MJ, Farrell J. Orthostatic Hypotension: A Practical Approach. American Family Physician. 2022; 105: 39–49.

[35] Sangolli PM, George NM. Small-Fiber Neuropathy. Clinical Dermatology Review. 2024; 8: 87–94. https://doi.org/10.4103/cdr.cdr_132_22.

[36] Dev B, Varkey A, Afsana H. Orthostatic Hypotension and Concomitant Paraneoplastic Syndromes: A Case Report. EMJ Neurology. 2023. Available at: https://www.emjreviews.com/neurology/article/orthostatic-hypotension-and-concomitant-paraneoplastic-syndromes-a-case-report/ (Accessed: 22 March 2025).

[37] Royal College of Physicians. How to measure lying and standing blood pressure (BP) as part of an assessment to optimise safe activity. 2023a. Available at: https://www.rcp.ac.uk/media/3oqbrkbx/fffap_how-to-measure-bp-v2.pdf (Accessed: 11 July 2025).

[38] Royal College of Physicians. Measurement of lying and standing blood pressure as part of a multi-factorial falls risk assessment. London: Royal College of Physicians. 2023b. Available at: https://www.rcp.ac.uk/media/grzk4plx/fffap_lying-and-standing-bp-procedure.pdf (Accessed: 8 July 2025).

[39] Guilleminault C. Clinical Neurophysiology of Sleep Disorders. Elsevier: Amsterdam. 2005.

[40] Eisenhofer G, Goldstein DS. Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension. Clinical Autonomic Research. 2021; 31: 351–353. https://doi.org/10.1007/s10286-021-00808-3.

[41] Panagiotides AM, Hever A, Sim JJ. An unusual presentation and etiology of hypotension seen in nephrotic syndrome. The Permanente Journal. 2009; 13: 55–57. https://doi.org/10.7812/TPP/08-084.

[42] Ravindran R, Carter JL, Kumar A, Capatana F, Khan IN, Adlan MA, et al. Pre-test Cortisol Levels in Predicting Short Synacthen Test Outcome: A Retrospective Analysis. Clinical Medicine Insights. Endocrinology and Diabetes. 2022; 15: 11795514221093316. https://doi.org/10.1177/11795514221093316.

[43] Hasrat NH, Kadhum HJ, Hashim AR, Yaqoob ZA, Kadhum LA, Farid HA. Neurophysiological changes by nerve conduction study and electromyography in acute and long-term COVID-19 circumstances: a comparative study protocol and review. Journal of Xi’an Shiyou University. 2022; 18: 241–249.

[44] BMJ Best Practice. Orthostatic hypotension: Symptoms, diagnosis and treatment. 2024. Available at: https://bestpractice.bmj.com/topics/en-gb/972 (Accessed: 28 April 2025).

[45] National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management (NICE guideline NG136). 2019. Available at: https://www.nice.org.uk/guidance/ng136 (Accessed: 28 March 2025).

[46] National Institute for Health and Care Excellence (NICE). Postural hypotension in adults: fludrocortisone. 2013. Available at: https://www.nice.org.uk/advice/esuom20/chapter/intervention-and-alternatives (Accessed: 22 March 2025).

[47] Whelton PK, Carey RM, Aronow WS, Casey DE, Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71: e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006.

[48] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39: 3021–3104. https://doi.org/10.1093/eurheartj/ehy339.

[49] Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. The Canadian Journal of Cardiology. 2018; 34: 506–525. https://doi.org/10.1016/j.cjca.2018.02.022.

[50] National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults. 2016. Available at: https://www.heartfoundation.org.au/getmedia/c83511ab-835a-4fcf-96f5-88d770582ddc/PRO-167_Hypertension-guideline-2016_WEB.pdf (Accessed: 28 March 2025).

[51] Van Campen CLMC, Visser FC. Psychogenic Pseudosyncope: Real or Imaginary? Results from a Case-Control Study in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients. Medicina. 2022; 58: 98. https://doi.org/10.3390/medicina58010098.

[52] Hofmeyr LM. Exploring the Experiences of Individuals Living with Recurrent Benign Paroxysmal Positional Vertigo (BPPV) in the Western Cape, South Africa [Doctoral dissertation]. Stellenbosch: Stellenbosch University. 2024.

[53] Mitra K, Kunte S, Taube S, Tian W, Richardson E, Frazier-Mills C, et al. Current Landscape of Compression Products for Treatment of Postural Orthostatic Tachycardia Syndrome and Neurogenic Orthostatic Hypotension. Journal of Clinical Medicine. 2024; 13: 7304. https://doi.org/10.3390/jcm13237304.

[54] British National Formulary. Midodrine hydrochloride: indications and dose. 2025b. Available at: https://bnf.nice.org.uk/drugs/midodrine-hydrochloride/#indications-and-dose (Accessed: 28 March 2025).

[55] British National Formulary. Fludrocortisone acetate. 2025a. Available at: https://bnf.nice.org.uk/drugs/fludrocortisone-acetate/ (Accessed: 23 March 2025).

[56] Min M, Shi T, Sun C, Liang M, Zhang Y, Bo G, et al. Orthostatic hypotension and the risk of atrial fibrillation and other cardiovascular diseases: An updated meta-analysis of prospective cohort studies. Journal of Clinical Hypertension. 2019; 21: 1221–1227. https://doi.org/10.1111/jch.13613.

[57] Ricci F, Fedorowski A, Radico F, Romanello M, Tatasciore A, Di Nicola M, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. European Heart Journal. 2015; 36: 1609–1617. https://doi.org/10.1093/eurheartj/ehv093.

[58] Briggs R, Carey D, Kennelly SP, Kenny RA. Longitudinal Association Between Orthostatic Hypotension at 30 Seconds Post-Standing and Late-Life Depression. Hypertension. 2018; 71: 946–954. https://doi.org/10.1161/HYPERTENSIONAHA.117.10542.

[59] Min M, Shi T, Sun C, Liang M, Zhang Y, Wu Y, et al. The association between orthostatic hypotension and dementia: A meta-analysis of prospective cohort studies. International Journal of Geriatric Psychiatry. 2018; 33: 1541–1547. https://doi.org/10.1002/gps.4964.

[60] Pasdar Z, De Paola L, Carter B, Pana TA, Potter JF, Myint PK. Orthostatic hypertension and major adverse events: a systematic review and meta-analysis. European Journal of Preventive Cardiology. 2023; 30: 1028–1038. https://doi.org/10.1093/eurjpc/zwad158.

[61] Magkas N, Tsioufis C, Thomopoulos C, Dilaveris P, Georgiopoulos G, Sanidas E, et al. Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. Journal of Clinical Hypertension. 2019; 21: 546–554. https://doi.org/10.1111/jch.13521.